Clarivate 2025 Drugs to Watch Report unveils blockbuster therapies
4 days ago · Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. This year, the highly …
Pharma USA 2025 - The Pharmaletter
5 days ago · A leading meeting for commercial, marketing, medical affairs, patient engagement, RWE, market access and patient leaders.
Calico next to fail in ALS | The Pharmaletter
5 days ago · Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. The Californian firm …
US FDA warning over counterfeit drugs bought in Mexico
May 15, 2005 · The US Food and Drug Administration is warning the public about the sale of counterfeit versions of Pfizer's Lipitor (atorvastatin) and Viagra (sildenafil), and an unapproved …
Novo Nordisk links up with Photys Thera on cardiometabolic targets
Dec 18, 2024 · Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel …
Focus on biosimilars yields record FDA approvals in 2024
4 days ago · The FDA approved 50 novel drugs in 2024, including 18 biosimilars, with many targeting rare diseases and offering interchangeable options. Over 74% of approvals occurred …
Light Horse emerges along with Novartis collaboration
3 days ago · USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant …
Subcutaneous Sarclisa scores Phase III win | Biotechnology | The ...
4 days ago · Sanofi reports positive Phase III results for a subcutaneous version of Sarclisa in relapsed or refractory multiple myeloma. Delivered via an on-body device, the treatment offers …
DBV up 10% as confidence grows in peanut patch
4 days ago · Shares in French food allergy biotech DBV Technologies (Nasdaq: DBVT) looked set to close more than 10% higher on Thursday. The company earlier announced positive 24 …
DiogenX | The Pharmaletter
Jul 25, 2024 · Company Overview. DiogenX is a preclinical stage company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Founded in 2020, its …